Vutiglabridin-R

Vutiglabridin-R (HSG4112-R) is a small molecule drug candidate being developed by Glaceum for the treatment of obesity in companion animals. It is the veterinary-specific version of HSG4112 (Vutiglabridin), a first-in-class metabolic modulator. The drug's mechanism of action involves the modulation of the Paraoxonase (PON) family of proteins, specifically Paraoxonase 1 (PON1), Paraoxonase 2 (PON2), and Paraoxonase 3 (PON3). These proteins are known to play critical roles in antioxidant defense and metabolic homeostasis. By targeting these proteins, Vutiglabridin-R aims to address the underlying metabolic dysfunction associated with obesity in pets, providing a potential novel therapeutic option for animal health management.

Other names

Vutiglabridin-RHSG4112-RHSG-4112-RHSG 4112-R